Ketanserin and ritanserin discriminate between recombinant human 5-HT1D alpha and 5-HT1D beta receptor subtypes. 1995

J M Zgombick, and L E Schechter, and S A Kucharewicz, and R L Weinshank, and T A Branchek
Synaptic Pharmaceutical Corporation, Paramus N.J. 07652, USA.

Compounds able to discriminate functionally between the closely related cloned human 5-HT1D alpha and 5-HT1D beta receptor subtypes have not been reported previously. In [3H]5-HT competition assays, the classical 5-HT2A receptor antagonists, ritanserin and ketanserin, displayed moderate affinity (pKi = 7.30 and 7.17, respectively) and marked selectivity (22- and 71-fold, respectively) for the recombinant human 5-HT1D alpha subtype relative to the 5-HT1D beta receptor. In contrast, the nonselective 5-HT1/2 receptor antagonist, methiothepin, exhibited similar binding affinities (pKi = 7.64-8.01) for both recombinant 5-HT1D subtypes. The antagonistic properties of these compounds were evaluated for their ability to block 5-HT-induced inhibition of forskolin-stimulated cAMP accumulation in intact cells stably expressing either 5-HT1D alpha or 5-HT1D beta receptors. All three compounds behaved as antagonists devoid of intrinsic activity in the functional assays. The apparent pKb values determined in functional assays closely matched their pKi values obtained in binding assays. Since ketanserin exhibits significant selectivity for the human 5-HT1D alpha receptor, this antagonist can be used as a pharmacological tool to discriminate between 5-HT1D alpha and 5-HT1D beta receptor-mediated responses in human tissues.

UI MeSH Term Description Entries
D007650 Ketanserin A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients. 3-(2-(4-(4-Fluorobenzoyl)piperidinol)ethyl)-2,4(1H,3H)-quinazolinedione,R-41,468,R-41468,R 41,468,R 41468,R41,468,R41468
D008719 Methiothepin A serotonin receptor antagonist in the CENTRAL NERVOUS SYSTEM used as an antipsychotic. Metitepine,Methiothepin Maleate,Methiothepine,Maleate, Methiothepin
D011869 Radioligand Assay Quantitative determination of receptor (binding) proteins in body fluids or tissue using radioactively labeled binding reagents (e.g., antibodies, intracellular receptors, plasma binders). Protein-Binding Radioassay,Radioreceptor Assay,Assay, Radioligand,Assay, Radioreceptor,Assays, Radioligand,Assays, Radioreceptor,Protein Binding Radioassay,Protein-Binding Radioassays,Radioassay, Protein-Binding,Radioassays, Protein-Binding,Radioligand Assays,Radioreceptor Assays
D011985 Receptors, Serotonin Cell-surface proteins that bind SEROTONIN and trigger intracellular changes which influence the behavior of cells. Several types of serotonin receptors have been recognized which differ in their pharmacology, molecular biology, and mode of action. 5-HT Receptor,5-HT Receptors,5-Hydroxytryptamine Receptor,5-Hydroxytryptamine Receptors,Receptors, Tryptamine,Serotonin Receptor,Serotonin Receptors,Tryptamine Receptor,Tryptamine Receptors,Receptors, 5-HT,Receptors, 5-Hydroxytryptamine,5 HT Receptor,5 HT Receptors,5 Hydroxytryptamine Receptor,5 Hydroxytryptamine Receptors,Receptor, 5-HT,Receptor, 5-Hydroxytryptamine,Receptor, Serotonin,Receptor, Tryptamine,Receptors, 5 HT,Receptors, 5 Hydroxytryptamine
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001667 Binding, Competitive The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements. Competitive Binding
D012702 Serotonin Antagonists Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or SEROTONIN RECEPTOR AGONISTS. 5-HT Antagonist,5-HT Antagonists,5-Hydroxytryptamine Antagonist,5-Hydroxytryptamine Antagonists,Antiserotonergic Agent,Antiserotonergic Agents,Serotonin Antagonist,Serotonin Blockader,Serotonin Blockaders,Serotonin Receptor Antagonist,Serotonin Receptor Blocker,Antagonists, 5-HT,Antagonists, 5-Hydroxytryptamine,Antagonists, Serotonin,Serotonin Receptor Antagonists,Serotonin Receptor Blockers,5 HT Antagonist,5 HT Antagonists,5 Hydroxytryptamine Antagonist,5 Hydroxytryptamine Antagonists,Agent, Antiserotonergic,Agents, Antiserotonergic,Antagonist, 5-HT,Antagonist, 5-Hydroxytryptamine,Antagonist, Serotonin,Antagonist, Serotonin Receptor,Antagonists, 5 HT,Antagonists, 5 Hydroxytryptamine,Antagonists, Serotonin Receptor,Blockader, Serotonin,Blockaders, Serotonin,Blocker, Serotonin Receptor,Blockers, Serotonin Receptor,Receptor Antagonist, Serotonin,Receptor Antagonists, Serotonin,Receptor Blocker, Serotonin,Receptor Blockers, Serotonin
D015290 Second Messenger Systems Systems in which an intracellular signal is generated in response to an intercellular primary messenger such as a hormone or neurotransmitter. They are intermediate signals in cellular processes such as metabolism, secretion, contraction, phototransduction, and cell growth. Examples of second messenger systems are the adenyl cyclase-cyclic AMP system, the phosphatidylinositol diphosphate-inositol triphosphate system, and the cyclic GMP system. Intracellular Second Messengers,Second Messengers,Intracellular Second Messenger,Messenger, Second,Messengers, Intracellular Second,Messengers, Second,Second Messenger,Second Messenger System,Second Messenger, Intracellular,Second Messengers, Intracellular,System, Second Messenger,Systems, Second Messenger
D016713 Ritanserin A selective and potent serotonin-2 antagonist that is effective in the treatment of a variety of syndromes related to anxiety and depression. The drug also improves the subjective quality of sleep and decreases portal pressure. 6-(2-(4-(Bis(4-fluorophenyl)methylene)-1-piperidinyl)ethyl)-7-methyl-5H-thiazolo(3,2-a)pyrimidin-5-one,R-55667,Ritanserin Hydrochloride,Ritanserin Tartrate,R 55667,R55667

Related Publications

J M Zgombick, and L E Schechter, and S A Kucharewicz, and R L Weinshank, and T A Branchek
January 1996, Naunyn-Schmiedeberg's archives of pharmacology,
J M Zgombick, and L E Schechter, and S A Kucharewicz, and R L Weinshank, and T A Branchek
December 1995, European journal of pharmacology,
J M Zgombick, and L E Schechter, and S A Kucharewicz, and R L Weinshank, and T A Branchek
October 1996, European journal of pharmacology,
J M Zgombick, and L E Schechter, and S A Kucharewicz, and R L Weinshank, and T A Branchek
July 1995, European journal of pharmacology,
J M Zgombick, and L E Schechter, and S A Kucharewicz, and R L Weinshank, and T A Branchek
April 1992, Proceedings of the National Academy of Sciences of the United States of America,
J M Zgombick, and L E Schechter, and S A Kucharewicz, and R L Weinshank, and T A Branchek
June 1996, European journal of pharmacology,
J M Zgombick, and L E Schechter, and S A Kucharewicz, and R L Weinshank, and T A Branchek
February 1995, Neuropharmacology,
J M Zgombick, and L E Schechter, and S A Kucharewicz, and R L Weinshank, and T A Branchek
December 1995, FEBS letters,
J M Zgombick, and L E Schechter, and S A Kucharewicz, and R L Weinshank, and T A Branchek
November 1995, Naunyn-Schmiedeberg's archives of pharmacology,
J M Zgombick, and L E Schechter, and S A Kucharewicz, and R L Weinshank, and T A Branchek
March 1996, Trends in pharmacological sciences,
Copied contents to your clipboard!